UTAH MEDICAL PRODUCTS INC
No enriched coverage for $UTMD in the last 7 days.
No SEC Form 4 filings for $UTMD in the last 30 days.
Utah Medical's Q3 earnings fell 20% year over year as order cancellations and tariffs pressured margins. Growth in U.S. Filshie devices and direct sales helped partially offset declines.
Utah Medical's Q2 earnings decrease year over year on lower OEM sales and weak international demand, though cost controls helped cushion margins.
JPM's strong NII outlook, NVS's blockbuster pipeline, and T's wireless momentum anchor today's top analyst picks.
